There are 2789 resources available
1438TiP - INTEGRATE IIb: A randomised phase III open label study of regorafenib + nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)
Presenter: Nick Pavlakis
Session: ePoster Display
1362TiP - Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study
Presenter: Pierre-Jean Souquet
Session: ePoster Display
1363TiP - A phase I/II study of TPX-0131, a novel oral ALK tyrosine kinase inhibitor, in patients with ALK+ advanced/metastatic NSCLC
Presenter: Ben Solomon
Session: ePoster Display
1364TiP - Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy
Presenter: Byoung Chul Cho
Session: ePoster Display
1365TiP - A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy
Presenter: Sun Min Lim
Session: ePoster Display
1366TiP - Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
Presenter: Yi-Long Wu
Session: ePoster Display
1367TiP - IMPRINTER: An open label, multi-center, dose escalation/expansion, phase I study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer
Presenter: Rita Laeufle
Session: ePoster Display